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Abstract
Objectives: In Parkinson´s disease, researchers are becoming increas-
ingly aware of the need to include the assessment of behavioural and 
psychological symptoms as important outcome measures in clinical tri-
als. Besides, clinicians are starting to recognise the need to identify and 
manage these symptoms in addition to the motor ones. Our objective 
is to explore the presence of neuropsychiatric symptoms in geriatric 
patients with Parkinson and the associated distress in their caregivers. 
Methods: 100 patients with PD ageing 75 years old or more (50 PD 
without dementia and 50 PD Dementia (PDD) were assessed using the 
10-item Neuropsychiatric Inventory-questionnaire (NPI-Q), and the NPI 
Caregiver Distress Scale (NPI-D). 
Results: The mean total NPI score was 12.9. At least one neuropsychi-
atric symptom was present in more than 80% of participants. Within 
PDD patients about 89% suffered at least one NPI symptom, 70% 
suffered at least 2 symptoms and one of those symptoms had an in-
tensity scoring 4 of higher in more than 50%. Numbers in PD patients 
without dementia were significantly lower, though more than 50% of 
patients had at least 2 symptoms. The most frequent symptom was 
depression, followed by apathy, anxiety, depression and hallucinations. 
Antiparkinsonian agents can exacerbate psychotic symptoms. Nearly 
60% of caregivers reported suffering a moderate to severe level of 
stress due to these symptoms. Symptoms causing more stress were 
agitation/aggression followed by hallucinations and irritability/lability. 
Conclusions: Neuropsychiatric symptoms are frequent in geriatric pa-
tients with PD –specially in patients with PDD– and lead to moderate 
to severe caregiver distress. 
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Introduction 
Frequent neuropsychiatric symptoms have been re-
ported in patients with neurodegenerative disorders, 
especially in Alzheimer’s and Lewy Bodies diseases, 
but also in PD. According to Aarsland, up to 89% of 
patients with PD have at least one NPI symptom and 
77% have two or more (1). Researchers are becom-
ing increasingly aware of the need to include the as-
sessment of behavioural and psychological symptoms 
as important outcome measures in clinical trials in 
Parkinsons´ disease (PD). Besides, clinicians are starting 
to recognise the need to identify and manage these 
symptoms early in addition to the motor ones.
Neuropsychiatric disturbances in PD patients con-
tribute considerably to reduce quality of life and 
increase both the distress for the caregiver and the 
risk of admission to nursing home. While PD can 
coexist with other common causes of dementia, 
such as Alzheimer disease (AD) and vascular de-
mentia (VD), dementia is increasingly recognised as 
a common feature of Parkinson disease itself. What 
is more, cognitive dysfunction is present in many 
patients without dementia (2) as it also happens in 
other alpha-synucleinpathies (3). Additionally, most 
patients with PD will eventually develop dementia, 
and previous studies found neuropsychiatric symp-
toms are more common and severe in PD when 
dementia is present (PDD) (4). 
Since neuropsychiatric symptoms in elderly pa-
tients have profound effects in their lives –and their 
caregivers– a detailed knowledge of these symptoms 
is needed to identify and manage them accurately. 
In spite of all epidemiological studies during recent 
years, to the best of our knowledge, no studies have 
specifically explored these symptoms in geriatric pa-
tients with PD or the associated stress in their car-
egivers. To reach this objective we administered the 
Neuropsychiatric Inventory (NPI-D and NPI-Q) to a 
sample of geriatric patients with PD and their car-
egivers. The validity of the NPI has been established, 
and high reliability in PD has been reported (5). 
Methods
Patients 
Patients were recruited from the Neurology and 
Geriatrics Units at Hospital Álvarez-Buylla (Mieres, 
Spain). Approval ethics committee at Hospital Uni-
versitario Central de Asturias was obtained. We 
invited to enrol consecutive patients meeting the 
inclusion criteria, up to completing the sample (100 
patients).We screened patients ageing at least 75 
years old diagnosed with PD according to the UK 
Parkinson’s Disease Brain Bank criteria (6). They were 
both patients without dementia (n=50) and patients 
with mild to moderately severe dementia (n=50) as 
defined by the Movement Disorder Society (7,8). 
In patients with PDD, the onset of dementia was 
required to appear at least 2 years after the diag-
nosis of idiopathic PD. Patients were also required 
to have contact with a responsible caregiver at least 
4 days a week. Exclusion criteria included any pri-
mary neurodegenerative disorder other than PD or 
any other causes of dementia, a history of alcohol 
abuse, and any disability or unstable disease that 
might prevent the patient from completing all study 
requirements. Participants and their caregivers gave 
informed consent. 
Keywords: Parkinson’s disease, neuropsychiatric symptoms, caregiver, 
geriatric, dementia.
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Clinical Evaluation 
Neuropsychiatric symptoms in patients and the im-
pact on stress of caregivers were assessed using the 
Brief Clinical Form of the Neuropsychiatric Inventory 
(NPI-Q) (9) and the Neuropsychiatric Inventory Car-
egiver Distress Scale (NPI-D) (10). Each domain of the 
NPI-Q is rated for frequency (1–4) and severity (1–3), 
and the overall score for a domain is the product of 
frequency and severity. On the NPI-D, each domain 
is rated for level of caregiver distress (level of distress: 
0;not at all, 1; minimal, 2; moderate, 3; severe, 4; very 
severe or extreme distress, 5). The NPI total scores are 
the sum of the individual domain scores, with higher 
scores indicating more serious behavioural symptoms 
(NPI-Q) or greater caregiver distress (NPI-D). No cut-
ting-point or reference values exist for this scale.
Cognition was assessed by means of Mini Mental 
State Examination (MMSE) (11) and Frontal Assess-
ment Battery (FAB) (12). Staging of PD was assessed 
by the Hoehn and Yahr scale (13). Pharmacologic 
treatment with antiparkinsonian agents and psy-
chotropic drugs was recorded. 
Statistical Analyses 
Descriptive statistics were applied first (mean, 
standard deviation (SD), rates) for sample descrip-
tion. Student’s t test was used for comparisons of 
normally distributed continuous data and χ2 test 
for categorical variables. Non-parametric tests were 
used for comparison of the NPI scores owing to the 
skewness and non-linearity of these data. A value 
of p<0.05 was considered significant. 
Results 
Sample Characteristics 
NPI was completed for 100 patients (56% men 
and 44% women). The age of the sample -mean 
(SD)- was 81.94 (3.61) years, and they had 6.00 
(5.06) years of formal education. The duration since 
onset of PD was 9.03 (5.9) years, and since diag-
nosis of dementia was 4.15 (2.7) years. The MMSE 
score was 18.23 (4.90), FAB 11.12 (2.4) and Hoehn 
and Yahr stage 2.84 (0.83). All patients were on 
antiparkinsonian agents, 39.4% used cholinesterase 
inhibitors, 34.4% used antipsychotic agents, 21.6% 
used antidepressants and 20.5% used anxiolytic 
agents. 19.1% used more than one type of psy-
chotropic drug apart from antiparkinsonian agents. 
Caregivers were family members in 87% of cases 
(spouse 47%, daughter 18%, son 12%, daughter-in-
law 8%, son-in-law 2%), while 13% were profes-
sional caregivers.
NPI-Q Scores in Patients
The mean (SD) total NPI score was 12.9 (12.0). 
The most prevalent symptoms were depression 
(53%), apathy (50%), anxiety (45%) and halluci-
nations (41%) (Figure 1). Patients with dementia 
had more neuropsychiatric symptoms than pa-
tients without dementia (p=0.03). Eighty-one per 
cent (81%) PDD patients presented at least one, 
70% had two or more symptoms and 56% had 
at least one symptom with a score ≥4. Numbers 
in PD patients without dementia were significantly 
lower, though more than 50% of patients had 2 
symptoms at least (Figure 1). 
Associations between NPI-Q and Clinical 
Characteristics 
The total NPI-Q score did not differ between 
male and female patients (p = 0.55), and we 
found no statistical association with age (r =−0.18; 
p =0.08). However, we found significant associa-
tions between total NPI score and cognitive impair-
ment (p = 0.04) and stage (p=0.04). Patients with 
a MMSE score below the median score of 18 had 
more neuropsychiatric symptoms than those with 
MMSE score >20: mean total NPI 15.02 (13.23) v 
11.19 (10.71); number of symptoms 3.7 (2.3) v 3.0 
(2.0); Mann–Whitney test; p = 0.04 for both). 
A similar pattern was found in the relationship 
between NPI items and Hoehn and Yahr stage. 
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Those with a Hoehn and Yahr stage at or above 
the median stage of 3 had a total NPI score of 15.33 
(11.14) compared with 10.15 (11.50) in those with a 
Hoehn and Yahr score <3 (p<0.02). 
A significant and direct correlation between 
symptoms and doses of antiparkinsonian agents was 
found both for agonists and levodopa: the higher 
doses the more severe symptoms (r = 0.88; p = 0.03). 
NPI-D scores in Caregivers 
58.6% of the caregivers reported at least one 
NPI symptom leading to moderate severe stress, 
that is, a score of ≥3. The highest caregiver distress 
score was found to be caused for agitation, hal-
lucination and irritability (Figure 2). Carers of PDD 
patients suffered more stress than those of patients 
without dementia (p=0.02) (Figure 2).
Figure 2. Caregivers stress reported as 
caused for neuropsychiatric symptoms. 
The highest caregiver distress score 
was found to be caused for agitation/
aggression, followed by hallucination 
and irritability/lability.
Figure 1. Prevalence and severity of neuropsychiatric 
symptoms in geriatric patients with PD. This figure 
shows results for the entire sample, including both 
patients with dementia and without dementia.  The 
most prevalent symptoms were depression (53%), 
apathy (50%), anxiety (45%) and hallucinations (41%).
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Discussion
Though PD was reported to be the synucleopa-
thy with less cognitive impairment and neuropsychi-
atric symptoms between all synucleopathies (14), in 
recent years,many studies reported high prevalence 
of these symptoms in PD patients (3,15). In this 
study, we explored the presence of neuropsychiat-
ric symptoms in a geriatric sample of patients with 
PD, both demented and non demented. At least 
one neuropsychiatric symptom was present in more 
than 80% of participants. Although some patients 
had few symptoms and low scores, a considerable 
number of patients had many symptoms, and 64% 
had a composite score of ≥4 for at least one item, 
indicating at least moderate severity. The most fre-
quent symptom was depression followed by anxi-
ety, apathy and hallucinations. These numbers are 
similar to Aarsland’s in patients with PD of any age, 
confirming these symptoms are prevalent in any PD 
population, regardless of its age. However in pa-
tients with early untreated PD, hallucinations were 
much less prevalent (16), suggesting that probably 
both age and dopaminergic agents are risk factors 
for suffering hallucinations. On the other hand, 
anxiety disorders decrease with age (35).
The frequency and severity of psychiatric symp-
toms in the PDD group were even higher than those 
reported in clinical trials for PDD (17,18) and the dis-
tribution of psychiatric symptoms differed markedly 
between PDD patients and patients with moderate 
to severe AD (19), including our own cohort (20). 
Hallucinations were more severe in PD patients, 
while aberrant motor behaviour, agitation, disinhi-
bition, irritability and euphoria were more severe 
in AD. In PDD, apathy was more common in mild 
Hoehn and Yahr stages, while delusions increased 
with more severe motor and cognitive disturbances. 
In PDD, only delusions correlated with the MMSE 
score. The cause for this difference may lie in dif-
ferential pathophysiology, as suggested by recent 
findings on morphological and neurochemical sub-
strates of delusions and hallucinations in demen-
tia with Lewy bodies, a disorder with clinical and 
neurobiological similarities toPDD (6, 21). Thus, the 
brain changes underlying psychosis in AD may differ 
from those in PDD, as has previously been shown 
for dementia with Lewy bodies and AD (22). 
Depression occurs in more than a half of geri-
atric PD patients and is associated with a range 
of comorbidities and leads to decreased quality of 
life (23). The profile of depressive symptoms in PD 
differs from that in depressed subjects without PD 
since patients with PD showed significant less re-
ported sadness, less anhedonia, less feelings of guilt 
and, slightly less loss of energy, but more concen-
tration problems than depressed control subjects 
(24). It may be predictive of cognitive decline (25), 
though a recent study shows that is apathy and 
not depression the symptom associated with deficit 
in implementing efficient cognitive strategies (26). 
Controversially, in the Norwegian ParkWest study, 
apathy was significantly associated with male gen-
der, higher depression scores and more severe mo-
tor symptoms, but was not with greater cognitive 
impairment. When excluding patients with signifi-
cant depressive symptoms, apathy remained signifi-
cantly associated with motor severity, suggesting a 
common underlying pathophysiological mechanism 
(27). Progression of motor signs predominantly me-
diated by non-dopaminergic systems (speech and 
axial impairment) may be a useful preclinical marker 
for incident apathy in PD (28). 
Psychosis is a frequent complication of PD, and it 
is characterized mainly by visual hallucinations and 
delusions, which are often paranoid in flavour. Hal-
lucinations are the most common manifestation, 
and they affect up to 40 percent of patients, par-
ticularly those with dementia (29,30). As we saw, 
the prevalence and severity of hallucinations in PD is 
higher in elderly patients, progressing over time. In 
non-demented PD patients, those with hallucinations 
are more likely to develop dementia than patients 
without this symptom (31,32) thereby announcing 
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dementia in many cases. Other manifestations of 
psychosis in PD include delusions, often paranoid 
and related to spousal infidelity and persecution (33). 
A variety of antiparkinsonian agents, most no-
tably anticholinergic agents, dopaminergic agents, 
and amantadine, can exacerbate neuropsychiatric 
symptoms in general, specially psychotic symptoms 
as visual hallucinations (34). All the antiparkinsonian 
drugs can give rise to hallucinations and psychosis, 
but the dopamine agonists are the ones with the 
greatest capacity to do so. Geriatric patients are 
even more sensitiveto these drugs and especial cau-
tion is needed when using antiparkinsonian drugs 
in geriatric PD patients. 
Panic disorder, generalised anxiety disorder and 
social phobia are prevalent anxiety disorders in PD 
(35). Comorbid depression with anxiety is frequently 
observed (36). The severity but not the duration of 
PD is positively related to anxiety. Anxiety disorders 
decrease with age and young onset PD patients are 
more likely to experience anxiety than the late onset 
ones (35).
Besides being common, the relevance of neu-
ropsychiatric symptoms in geriatric patients with 
PD is further underlined by the finding that nearly 
60% of the caregivers reported at least one NPI 
symptom leading to moderate or severe distress. 
However, the symptoms related with a more im-
portant contribution to caregiver stress are not the 
more frequent in patients, those are agitation/ag-
gression, hallucinations and irritabilify/lability. This 
means that some symptoms (mood and anxiety dis-
orders) do not lead to as much stress in caregivers 
of geriatric PD patients as behavioural symptoms 
do. Although some other studies failed to identify 
stress in caregivers derived from neuropsychiatric 
symptoms (37), more extensive studies also found 
this association, specially for those patients with 
dementia (38). An interesting study examined the 
level of agreement between caregiver and PD pa-
tient reports of neuropsychiatric problems reporting 
a low level of agreement (39). This may represent 
patients do not live these problems the same way 
their carers do. This correlates with the fact that in 
our study the more frequent and severe symptoms 
in the NPI-Q are not those with the higher score in 
the NPI-D. In the Norwegian ParkWest study, fo-
cused on newly diagnosed PD, the symptoms lead-
ing to caregiver stress are exactly the same that we 
found as more frequent in geriatric patients (40). 
Thus suggesting that, in early stages, the symptoms 
leading to caregiver stress are the more prevalent 
ones, while the relative influence of symptoms on 
caregiver stress changes with time when the disease 
evolves and psychotic and behavioural symptoms 
are more severe.
Conclusions
In conclusion, we found a high prevalence of 
neuropsychiatric symptoms in geriatric PD patients. 
These symptoms lead to moderate to severe stress 
in their caregivers. The profile of these symptoms 
differs from that in other types of dementia as AD 
but is similar to the youngest PD patients. Our find-
ings have implications for the appreciation, under-
standing and management of geriatric patients and 
their carers.
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